S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Janjigian
    Janjigian
  8. Jhanwar
    Jhanwar
  9. Tang
    Tang
  10. Clarkson
    Clarkson

Groups

  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Thoracic Oncology (45)
  10. Department of Pathology and Laboratory Medicine (43)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (255)
  3. Book Section (20)
  4. Review (16)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (5)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (635)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Entitäten-unabhängige sicherheit und wirksamkeit von erdafitinib bei patienten mit fortgeschrittenen soliden tumoren mit präspezifizierten genomischen fgfraberrationen (RAGNAR Interimanalyse)
    Meeting Abstract

    Schuler, M.; Loriot, Y.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Palmer, D. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • 96-Wochen update aus der phase 3 ASCEMBL studie zur untersuchung von sicherheit und wirksamkeit von asciminib vs. bosutinib bei patienten mit chronischer myeloischer leukämie in chronischer phase nach vorbehandlung mit 2 TKI
    Meeting Abstract

    Hochhaus, A.; Réa, D.; Saussele, S.; Buske, S.; Balabanov, S.; Lang, F.; Sauer, T.; Gattermann, N.; Mauro, M.; Minami, Y.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to lutetium-177-DOTATATE
    Journal Article

    Raj, N.; Coffman, K.; Le, T.; Do, R. K. G.; Rafailov, J.; Choi, Y.; Chou, J. F.; Capanu, M.; Dunphy, M.; Fox, J. J.; more...
    Neuroendocrinology (2022)

    Fulltext@MSK | Save
  • Quality issues in diagnostic immunohistochemistry in breast pathology
    Review

    Hoda, R. S.; Brogi, E.; Wen, H. Y.
    Pathobiology (2022)

    Fulltext@MSK | Save
  • Advances in the etiology, detection, and clinical management of seborrheic keratoses
    Review

    Sun, M. D.; Halpern, A. C.
    Dermatology (2022)

    Fulltext@MSK | Save
  • Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms
    Meeting Abstract

    Grünwald, V.; Hutson, T.; Choueiri, T. K.; Motzer, R.; Rha, S. Y.; Alyasova, A.; Merchan, J.; Gurney, H.; Peer, A.; Takagi, T.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • MERMAID-2: Phase 3 study of durvalumab in patients with resected, stage II-III NSCLC who become MRD plus after curative-intent therapy
    Meeting Abstract

    Reinmuth, N.; Spigel, D.; Peters, S.; Ahn, M. J.; Tsuboi, M.; Chaft, J.; Harpole, D.; Barlesi, F.; Abbosh, C.; Mann, H.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • The CAR-HEMATOTOX model identifies patients with a high risk for CAR T-cell related hematotoxicity and is associated with prolonged hospitalization and poor prognosis
    Meeting Abstract

    Rejeski, K.; Perez, A.; Sesques, P.; Berger, C.; Jentzsch, L.; Mougiakakos, D.; Frölich, L.; Ackermann, J.; Bücklein, V.; Blumenberg, V.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) with adjuvant nivolumab (NIVO) vs placebo (PBO) after radical resection for high-risk muscle-invasive urothelial carcinoma (MIUC): Results from the phase 3 CheckMate 274 trialep138
    Meeting Abstract

    Gschwend, J. E.; Bajorin, D.; Galsky, M.; Broughton, E.; Braverman, J.; Koon, H.; Maira-Arce, M.; Hamilton, M.; Shi, L.; Guo, S.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Matterhorn: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, doubleblind, placebo-controlled, phase 3 study
    Meeting Abstract

    Al-Batran, S. E.; Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Hyung, W. J.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S. H.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save